Page results
-
This page aims to support and supplement the information provided in the video titled Managing the Emotional Impact of Cancer, available on uclh.nhs.uk/wellbeing.
-
Stroke services at UCLH provide the best possible clinical care for all phases of the stroke pathway.
-
UCLH Pain Management Centre is a nationally recognized centre of excellence for people with longstanding pain.
-
The Royal National ENT Voice Centre is a national and international multidisciplinary centre for voice disorders. The voice clinic at the RNENT is one of the oldest in the UK.
-
The LTFU service caters primarily for young people and adults treated in the paediatric cancer service at Great Ormond Street Hospital (GOSH), and young people and adults treated in the Teenage and Young Adult service at University College Hospital.
-
Functional dyspepsia and gastroparesis often co-exist. There are good treatment pathways for managing the symptoms associated with these conditions.
-
The Upper GI service provides treatment for, amongst other conditions, oesophageal and gastric cancers as well as for benign conditions (acid reflux and motility disorders). There is close collaboration with the GI physiology and laser centre.
-
Our clinical neurophysiology department performs tests which record information from the brain or the nervous system. There are two main tests performed in our outpatient department, Electroencephalogram (EEG) and Nerve conduction studies (NCS).
-
This clinic provides a service within North Central London to children and young people up to 18 years of age with unusual, complicated or recurrent infections. A family infection clinic is also provided where family groups may be reviewed together by both adult and paediatric teams.
-
CAR T-cell therapy is a cutting-edge treatment for certain blood cancers, offering new hope to patients whose illness hasn’t responded to standard treatments. University College London Hospitals (UCLH) is proud to be one of Europe’s leading centres for this advanced care.
File results
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0327 - NHS long-term plan/ prevention strategy
-
FOI/2023/0330 - Outsourced/ in-house occupational health provisions
-
FOI/2023/0343 - Clinical guidelines - group B Streptococcus for antenatal, intrapartum and postnatal care
-
FOI/2022/0663 - Migraine treatment
-
FOI/2023/0344 - Number of neonatal and stillbirth deaths since January 2013
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0342 - Self-administration of medication policies